nodes	percent_of_prediction	percent_of_DWPC	metapath
Valsartan—ALB—Crohn's disease	0.51	1	CbGaD
Valsartan—SLCO1B1—Sulfasalazine—Crohn's disease	0.185	0.696	CbGbCtD
Valsartan—ALB—Prednisone—Crohn's disease	0.0808	0.304	CbGbCtD
Valsartan—Hamman-Rich syndrome—Mesalazine—Crohn's disease	0.0237	0.134	CcSEcCtD
Valsartan—Idiopathic pulmonary fibrosis—Mesalazine—Crohn's disease	0.0237	0.134	CcSEcCtD
Valsartan—Acute interstitial pneumonitis—Mesalazine—Crohn's disease	0.0237	0.134	CcSEcCtD
Valsartan—AGTR1—Arf6 trafficking events—VAMP3—Crohn's disease	0.00579	0.121	CbGpPWpGaD
Valsartan—Renal failure chronic—Mesalazine—Crohn's disease	0.00529	0.03	CcSEcCtD
Valsartan—Blood potassium increased—Prednisone—Crohn's disease	0.0025	0.0141	CcSEcCtD
Valsartan—Vasculitis—Azathioprine—Crohn's disease	0.0016	0.00907	CcSEcCtD
Valsartan—Hepatic enzyme increased—Mesalazine—Crohn's disease	0.00151	0.00853	CcSEcCtD
Valsartan—Blood urea increased—Mesalazine—Crohn's disease	0.00135	0.00762	CcSEcCtD
Valsartan—AGTR1—Allograft Rejection—LRRK2—Crohn's disease	0.00126	0.0263	CbGpPWpGaD
Valsartan—SLCO1B3—Transport of organic anions—ALB—Crohn's disease	0.00123	0.0256	CbGpPWpGaD
Valsartan—AGTR1—Peptide GPCRs—CCR9—Crohn's disease	0.00122	0.0253	CbGpPWpGaD
Valsartan—Immune system disorder—Mercaptopurine—Crohn's disease	0.00119	0.00674	CcSEcCtD
Valsartan—Photosensitivity—Mesalazine—Crohn's disease	0.00118	0.00667	CcSEcCtD
Valsartan—Alopecia—Mercaptopurine—Crohn's disease	0.00117	0.0066	CcSEcCtD
Valsartan—Malnutrition—Mercaptopurine—Crohn's disease	0.00115	0.0065	CcSEcCtD
Valsartan—Renal failure acute—Mesalazine—Crohn's disease	0.00112	0.00634	CcSEcCtD
Valsartan—Atrial fibrillation—Mesalazine—Crohn's disease	0.00109	0.00618	CcSEcCtD
Valsartan—Renal impairment—Mesalazine—Crohn's disease	0.00109	0.00615	CcSEcCtD
Valsartan—Dermatitis bullous—Mesalazine—Crohn's disease	0.00108	0.00613	CcSEcCtD
Valsartan—Arthralgia—Mercaptopurine—Crohn's disease	0.000978	0.00553	CcSEcCtD
Valsartan—Unspecified disorder of skin and subcutaneous tissue—Mercaptopurine—Crohn's disease	0.000971	0.00549	CcSEcCtD
Valsartan—Blood creatinine increased—Mesalazine—Crohn's disease	0.000969	0.00549	CcSEcCtD
Valsartan—Abdominal pain upper—Mesalazine—Crohn's disease	0.000945	0.00535	CcSEcCtD
Valsartan—Orthostatic hypotension—Mesalazine—Crohn's disease	0.000945	0.00535	CcSEcCtD
Valsartan—Oedema—Mercaptopurine—Crohn's disease	0.000937	0.0053	CcSEcCtD
Valsartan—Cramp muscle—Mesalazine—Crohn's disease	0.000932	0.00527	CcSEcCtD
Valsartan—Thrombocytopenia—Mercaptopurine—Crohn's disease	0.000918	0.00519	CcSEcCtD
Valsartan—Skin disorder—Mercaptopurine—Crohn's disease	0.00091	0.00515	CcSEcCtD
Valsartan—SLCO1B3—Recycling of bile acids and salts—ALB—Crohn's disease	0.000909	0.0189	CbGpPWpGaD
Valsartan—Anorexia—Mercaptopurine—Crohn's disease	0.000893	0.00505	CcSEcCtD
Valsartan—AGTR1—Arf6 trafficking events—ITGA4—Crohn's disease	0.00089	0.0186	CbGpPWpGaD
Valsartan—Infestation—Azathioprine—Crohn's disease	0.000876	0.00495	CcSEcCtD
Valsartan—Infestation NOS—Azathioprine—Crohn's disease	0.000876	0.00495	CcSEcCtD
Valsartan—AGTR1—Peptide ligand-binding receptors—ACKR2—Crohn's disease	0.00087	0.0181	CbGpPWpGaD
Valsartan—Bronchitis—Mesalazine—Crohn's disease	0.00086	0.00487	CcSEcCtD
Valsartan—Musculoskeletal discomfort—Mercaptopurine—Crohn's disease	0.000854	0.00483	CcSEcCtD
Valsartan—Neutropenia—Mesalazine—Crohn's disease	0.000836	0.00473	CcSEcCtD
Valsartan—AGTR1—G alpha (q) signalling events—MLN—Crohn's disease	0.000835	0.0174	CbGpPWpGaD
Valsartan—Viral infection—Prednisone—Crohn's disease	0.000835	0.00473	CcSEcCtD
Valsartan—Upper respiratory tract infection—Mesalazine—Crohn's disease	0.000831	0.0047	CcSEcCtD
Valsartan—AGTR1—Peptide ligand-binding receptors—MLN—Crohn's disease	0.000825	0.0172	CbGpPWpGaD
Valsartan—SLCO1B1—Transport of organic anions—ALB—Crohn's disease	0.000824	0.0172	CbGpPWpGaD
Valsartan—Photosensitivity reaction—Mesalazine—Crohn's disease	0.000816	0.00462	CcSEcCtD
Valsartan—Decreased appetite—Mercaptopurine—Crohn's disease	0.000815	0.00461	CcSEcCtD
Valsartan—Gastrointestinal disorder—Mercaptopurine—Crohn's disease	0.000809	0.00458	CcSEcCtD
Valsartan—AGTR1—Peptide GPCRs—CCR6—Crohn's disease	0.000805	0.0168	CbGpPWpGaD
Valsartan—Infestation—Mesalazine—Crohn's disease	0.000797	0.00451	CcSEcCtD
Valsartan—Infestation NOS—Mesalazine—Crohn's disease	0.000797	0.00451	CcSEcCtD
Valsartan—Haemoglobin—Azathioprine—Crohn's disease	0.00079	0.00447	CcSEcCtD
Valsartan—Haemorrhage—Azathioprine—Crohn's disease	0.000786	0.00445	CcSEcCtD
Valsartan—Renal failure—Mesalazine—Crohn's disease	0.000784	0.00444	CcSEcCtD
Valsartan—Vasculitis—Prednisone—Crohn's disease	0.000773	0.00437	CcSEcCtD
Valsartan—Epistaxis—Mesalazine—Crohn's disease	0.000752	0.00426	CcSEcCtD
Valsartan—Sinusitis—Mesalazine—Crohn's disease	0.000748	0.00423	CcSEcCtD
Valsartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—MLN—Crohn's disease	0.000747	0.0156	CbGpPWpGaD
Valsartan—Haemoglobin—Mesalazine—Crohn's disease	0.00072	0.00407	CcSEcCtD
Valsartan—Rhinitis—Mesalazine—Crohn's disease	0.000718	0.00406	CcSEcCtD
Valsartan—Haemorrhage—Mesalazine—Crohn's disease	0.000716	0.00405	CcSEcCtD
Valsartan—Hepatitis—Mesalazine—Crohn's disease	0.000716	0.00405	CcSEcCtD
Valsartan—Pharyngitis—Mesalazine—Crohn's disease	0.000711	0.00402	CcSEcCtD
Valsartan—Immune system disorder—Azathioprine—Crohn's disease	0.00071	0.00402	CcSEcCtD
Valsartan—Mediastinal disorder—Azathioprine—Crohn's disease	0.000708	0.00401	CcSEcCtD
Valsartan—Urinary tract disorder—Mesalazine—Crohn's disease	0.000707	0.004	CcSEcCtD
Valsartan—Connective tissue disorder—Mesalazine—Crohn's disease	0.000704	0.00398	CcSEcCtD
Valsartan—Urethral disorder—Mesalazine—Crohn's disease	0.000702	0.00397	CcSEcCtD
Valsartan—Alopecia—Azathioprine—Crohn's disease	0.000695	0.00393	CcSEcCtD
Valsartan—Hypersensitivity—Mercaptopurine—Crohn's disease	0.00069	0.00391	CcSEcCtD
Valsartan—AGTR1—GPCRs, Class A Rhodopsin-like—ACKR2—Crohn's disease	0.000681	0.0142	CbGpPWpGaD
Valsartan—Cardiac disorder—Mesalazine—Crohn's disease	0.000664	0.00376	CcSEcCtD
Valsartan—AGTR1—Allograft Rejection—IL17A—Crohn's disease	0.000663	0.0138	CbGpPWpGaD
Valsartan—Angiopathy—Mesalazine—Crohn's disease	0.00065	0.00368	CcSEcCtD
Valsartan—Immune system disorder—Mesalazine—Crohn's disease	0.000647	0.00366	CcSEcCtD
Valsartan—Mediastinal disorder—Mesalazine—Crohn's disease	0.000645	0.00365	CcSEcCtD
Valsartan—Diarrhoea—Mercaptopurine—Crohn's disease	0.000641	0.00363	CcSEcCtD
Valsartan—Alopecia—Mesalazine—Crohn's disease	0.000633	0.00358	CcSEcCtD
Valsartan—Mental disorder—Mesalazine—Crohn's disease	0.000627	0.00355	CcSEcCtD
Valsartan—AGTR1—Allograft Rejection—IL12B—Crohn's disease	0.000616	0.0128	CbGpPWpGaD
Valsartan—Flatulence—Mesalazine—Crohn's disease	0.000614	0.00347	CcSEcCtD
Valsartan—SLCO1B1—Recycling of bile acids and salts—ALB—Crohn's disease	0.000611	0.0127	CbGpPWpGaD
Valsartan—Dysgeusia—Mesalazine—Crohn's disease	0.00061	0.00345	CcSEcCtD
Valsartan—Back pain—Mesalazine—Crohn's disease	0.000603	0.00341	CcSEcCtD
Valsartan—Muscle spasms—Mesalazine—Crohn's disease	0.000599	0.00339	CcSEcCtD
Valsartan—Vomiting—Mercaptopurine—Crohn's disease	0.000596	0.00337	CcSEcCtD
Valsartan—Rash—Mercaptopurine—Crohn's disease	0.000591	0.00334	CcSEcCtD
Valsartan—Dermatitis—Mercaptopurine—Crohn's disease	0.00059	0.00334	CcSEcCtD
Valsartan—Vision blurred—Mesalazine—Crohn's disease	0.000587	0.00332	CcSEcCtD
Valsartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—ACKR2—Crohn's disease	0.000584	0.0122	CbGpPWpGaD
Valsartan—Myalgia—Azathioprine—Crohn's disease	0.000582	0.0033	CcSEcCtD
Valsartan—Arthralgia—Azathioprine—Crohn's disease	0.000582	0.0033	CcSEcCtD
Valsartan—Unspecified disorder of skin and subcutaneous tissue—Azathioprine—Crohn's disease	0.000578	0.00327	CcSEcCtD
Valsartan—AGTR1—Peptide ligand-binding receptors—CCR9—Crohn's disease	0.000572	0.0119	CbGpPWpGaD
Valsartan—Angioedema—Mesalazine—Crohn's disease	0.000569	0.00322	CcSEcCtD
Valsartan—Cardiac failure—Prednisone—Crohn's disease	0.000561	0.00317	CcSEcCtD
Valsartan—Vertigo—Mesalazine—Crohn's disease	0.00056	0.00317	CcSEcCtD
Valsartan—Syncope—Mesalazine—Crohn's disease	0.000559	0.00316	CcSEcCtD
Valsartan—Nausea—Mercaptopurine—Crohn's disease	0.000557	0.00315	CcSEcCtD
Valsartan—Infection—Azathioprine—Crohn's disease	0.000555	0.00314	CcSEcCtD
Valsartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—MLN—Crohn's disease	0.000553	0.0115	CbGpPWpGaD
Valsartan—Palpitations—Mesalazine—Crohn's disease	0.000551	0.00312	CcSEcCtD
Valsartan—Loss of consciousness—Mesalazine—Crohn's disease	0.000548	0.0031	CcSEcCtD
Valsartan—Thrombocytopenia—Azathioprine—Crohn's disease	0.000547	0.00309	CcSEcCtD
Valsartan—Cough—Mesalazine—Crohn's disease	0.000544	0.00308	CcSEcCtD
Valsartan—Skin disorder—Azathioprine—Crohn's disease	0.000542	0.00307	CcSEcCtD
Valsartan—AGTR1—G alpha (q) signalling events—GPR65—Crohn's disease	0.000538	0.0112	CbGpPWpGaD
Valsartan—Arthralgia—Mesalazine—Crohn's disease	0.000531	0.003	CcSEcCtD
Valsartan—Chest pain—Mesalazine—Crohn's disease	0.000531	0.003	CcSEcCtD
Valsartan—Myalgia—Mesalazine—Crohn's disease	0.000531	0.003	CcSEcCtD
Valsartan—Anxiety—Mesalazine—Crohn's disease	0.000529	0.00299	CcSEcCtD
Valsartan—Unspecified disorder of skin and subcutaneous tissue—Mesalazine—Crohn's disease	0.000527	0.00298	CcSEcCtD
Valsartan—Hypotension—Azathioprine—Crohn's disease	0.000522	0.00295	CcSEcCtD
Valsartan—Dry mouth—Mesalazine—Crohn's disease	0.000519	0.00294	CcSEcCtD
Valsartan—Musculoskeletal discomfort—Azathioprine—Crohn's disease	0.000509	0.00288	CcSEcCtD
Valsartan—Anaphylactic shock—Mesalazine—Crohn's disease	0.000509	0.00288	CcSEcCtD
Valsartan—Oedema—Mesalazine—Crohn's disease	0.000509	0.00288	CcSEcCtD
Valsartan—Infection—Mesalazine—Crohn's disease	0.000505	0.00286	CcSEcCtD
Valsartan—Shock—Mesalazine—Crohn's disease	0.0005	0.00283	CcSEcCtD
Valsartan—Nervous system disorder—Mesalazine—Crohn's disease	0.000499	0.00282	CcSEcCtD
Valsartan—Thrombocytopenia—Mesalazine—Crohn's disease	0.000498	0.00282	CcSEcCtD
Valsartan—Skin disorder—Mesalazine—Crohn's disease	0.000494	0.0028	CcSEcCtD
Valsartan—Anorexia—Mesalazine—Crohn's disease	0.000485	0.00274	CcSEcCtD
Valsartan—Muscular weakness—Prednisone—Crohn's disease	0.000483	0.00273	CcSEcCtD
Valsartan—Gastrointestinal disorder—Azathioprine—Crohn's disease	0.000482	0.00273	CcSEcCtD
Valsartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—GPR65—Crohn's disease	0.000482	0.01	CbGpPWpGaD
Valsartan—Hypotension—Mesalazine—Crohn's disease	0.000475	0.00269	CcSEcCtD
Valsartan—SLCO1B3—Bile acid and bile salt metabolism—ALB—Crohn's disease	0.000475	0.0099	CbGpPWpGaD
Valsartan—Musculoskeletal discomfort—Mesalazine—Crohn's disease	0.000463	0.00262	CcSEcCtD
Valsartan—Insomnia—Mesalazine—Crohn's disease	0.00046	0.0026	CcSEcCtD
Valsartan—Paraesthesia—Mesalazine—Crohn's disease	0.000457	0.00258	CcSEcCtD
Valsartan—Gastrointestinal pain—Azathioprine—Crohn's disease	0.000457	0.00258	CcSEcCtD
Valsartan—SLCO1B3—Transport of vitamins, nucleosides, and related molecules—ALB—Crohn's disease	0.000455	0.00948	CbGpPWpGaD
Valsartan—Dyspnoea—Mesalazine—Crohn's disease	0.000453	0.00257	CcSEcCtD
Valsartan—Somnolence—Mesalazine—Crohn's disease	0.000452	0.00256	CcSEcCtD
Valsartan—AGTR1—Allograft Rejection—IL10—Crohn's disease	0.00045	0.00939	CbGpPWpGaD
Valsartan—Dyspepsia—Mesalazine—Crohn's disease	0.000448	0.00253	CcSEcCtD
Valsartan—AGTR1—GPCRs, Class A Rhodopsin-like—CCR9—Crohn's disease	0.000448	0.00933	CbGpPWpGaD
Valsartan—AGTR1—GPCR ligand binding—ACKR2—Crohn's disease	0.000444	0.00926	CbGpPWpGaD
Valsartan—Neutropenia—Prednisone—Crohn's disease	0.000443	0.0025	CcSEcCtD
Valsartan—Decreased appetite—Mesalazine—Crohn's disease	0.000442	0.0025	CcSEcCtD
Valsartan—Abdominal pain—Azathioprine—Crohn's disease	0.000441	0.0025	CcSEcCtD
Valsartan—Gastrointestinal disorder—Mesalazine—Crohn's disease	0.000439	0.00248	CcSEcCtD
Valsartan—Fatigue—Mesalazine—Crohn's disease	0.000439	0.00248	CcSEcCtD
Valsartan—Erectile dysfunction—Prednisone—Crohn's disease	0.000436	0.00247	CcSEcCtD
Valsartan—SLCO1B3—SLC-mediated transmembrane transport—SLC22A4—Crohn's disease	0.000436	0.00908	CbGpPWpGaD
Valsartan—SLCO1B3—SLC-mediated transmembrane transport—SLC22A5—Crohn's disease	0.000436	0.00908	CbGpPWpGaD
Valsartan—Constipation—Mesalazine—Crohn's disease	0.000435	0.00246	CcSEcCtD
Valsartan—AGTR1—GPCR ligand binding—MLN—Crohn's disease	0.000421	0.00878	CbGpPWpGaD
Valsartan—AGTR1—GPCRs, Class A Rhodopsin-like—GPR65—Crohn's disease	0.000416	0.00867	CbGpPWpGaD
Valsartan—Gastrointestinal pain—Mesalazine—Crohn's disease	0.000416	0.00235	CcSEcCtD
Valsartan—Hypersensitivity—Azathioprine—Crohn's disease	0.000411	0.00233	CcSEcCtD
Valsartan—Urticaria—Mesalazine—Crohn's disease	0.000404	0.00229	CcSEcCtD
Valsartan—Abdominal pain—Mesalazine—Crohn's disease	0.000402	0.00228	CcSEcCtD
Valsartan—AGTR1—Allograft Rejection—IL2RA—Crohn's disease	0.000401	0.00837	CbGpPWpGaD
Valsartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—CCR9—Crohn's disease	0.000384	0.00799	CbGpPWpGaD
Valsartan—Diarrhoea—Azathioprine—Crohn's disease	0.000382	0.00216	CcSEcCtD
Valsartan—Haemoglobin—Prednisone—Crohn's disease	0.000381	0.00215	CcSEcCtD
Valsartan—Haemorrhage—Prednisone—Crohn's disease	0.000379	0.00214	CcSEcCtD
Valsartan—AGTR1—Peptide ligand-binding receptors—CCR6—Crohn's disease	0.000379	0.00789	CbGpPWpGaD
Valsartan—Hypersensitivity—Mesalazine—Crohn's disease	0.000375	0.00212	CcSEcCtD
Valsartan—CYP2C9—Arachidonic acid metabolism—GPX4—Crohn's disease	0.000373	0.00778	CbGpPWpGaD
Valsartan—Connective tissue disorder—Prednisone—Crohn's disease	0.000372	0.00211	CcSEcCtD
Valsartan—Dizziness—Azathioprine—Crohn's disease	0.000369	0.00209	CcSEcCtD
Valsartan—ALB—Folate Metabolism—GPX4—Crohn's disease	0.000365	0.00761	CbGpPWpGaD
Valsartan—Asthenia—Mesalazine—Crohn's disease	0.000365	0.00206	CcSEcCtD
Valsartan—Pruritus—Mesalazine—Crohn's disease	0.00036	0.00204	CcSEcCtD
Valsartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—GPR65—Crohn's disease	0.000357	0.00743	CbGpPWpGaD
Valsartan—Vomiting—Azathioprine—Crohn's disease	0.000355	0.00201	CcSEcCtD
Valsartan—Rash—Azathioprine—Crohn's disease	0.000352	0.00199	CcSEcCtD
Valsartan—Dermatitis—Azathioprine—Crohn's disease	0.000352	0.00199	CcSEcCtD
Valsartan—Headache—Azathioprine—Crohn's disease	0.00035	0.00198	CcSEcCtD
Valsartan—Diarrhoea—Mesalazine—Crohn's disease	0.000348	0.00197	CcSEcCtD
Valsartan—Angiopathy—Prednisone—Crohn's disease	0.000344	0.00194	CcSEcCtD
Valsartan—ALB—Vitamin B12 Metabolism—MPO—Crohn's disease	0.000342	0.00713	CbGpPWpGaD
Valsartan—Immune system disorder—Prednisone—Crohn's disease	0.000342	0.00194	CcSEcCtD
Valsartan—Dizziness—Mesalazine—Crohn's disease	0.000336	0.0019	CcSEcCtD
Valsartan—Alopecia—Prednisone—Crohn's disease	0.000335	0.00189	CcSEcCtD
Valsartan—Mental disorder—Prednisone—Crohn's disease	0.000332	0.00188	CcSEcCtD
Valsartan—Nausea—Azathioprine—Crohn's disease	0.000332	0.00188	CcSEcCtD
Valsartan—Malnutrition—Prednisone—Crohn's disease	0.00033	0.00187	CcSEcCtD
Valsartan—Vomiting—Mesalazine—Crohn's disease	0.000323	0.00183	CcSEcCtD
Valsartan—Rash—Mesalazine—Crohn's disease	0.000321	0.00181	CcSEcCtD
Valsartan—Dermatitis—Mesalazine—Crohn's disease	0.00032	0.00181	CcSEcCtD
Valsartan—SLCO1B1—Bile acid and bile salt metabolism—ALB—Crohn's disease	0.000319	0.00665	CbGpPWpGaD
Valsartan—Headache—Mesalazine—Crohn's disease	0.000319	0.0018	CcSEcCtD
Valsartan—ALB—Platelet degranulation—F5—Crohn's disease	0.000317	0.00661	CbGpPWpGaD
Valsartan—Vision blurred—Prednisone—Crohn's disease	0.000311	0.00176	CcSEcCtD
Valsartan—SLCO1B3—SLC-mediated transmembrane transport—GCKR—Crohn's disease	0.000307	0.0064	CbGpPWpGaD
Valsartan—SLCO1B1—Transport of vitamins, nucleosides, and related molecules—ALB—Crohn's disease	0.000306	0.00637	CbGpPWpGaD
Valsartan—Nausea—Mesalazine—Crohn's disease	0.000302	0.00171	CcSEcCtD
Valsartan—ALB—Response to elevated platelet cytosolic Ca2+—F5—Crohn's disease	0.000302	0.00629	CbGpPWpGaD
Valsartan—Angioedema—Prednisone—Crohn's disease	0.000301	0.0017	CcSEcCtD
Valsartan—AGTR1—GPCRs, Class A Rhodopsin-like—CCR6—Crohn's disease	0.000297	0.00618	CbGpPWpGaD
Valsartan—Vertigo—Prednisone—Crohn's disease	0.000296	0.00168	CcSEcCtD
Valsartan—Syncope—Prednisone—Crohn's disease	0.000296	0.00167	CcSEcCtD
Valsartan—SLCO1B1—SLC-mediated transmembrane transport—SLC22A5—Crohn's disease	0.000293	0.0061	CbGpPWpGaD
Valsartan—SLCO1B1—SLC-mediated transmembrane transport—SLC22A4—Crohn's disease	0.000293	0.0061	CbGpPWpGaD
Valsartan—AGTR1—GPCR ligand binding—CCR9—Crohn's disease	0.000292	0.00609	CbGpPWpGaD
Valsartan—ALB—Selenium Micronutrient Network—GPX4—Crohn's disease	0.00029	0.00605	CbGpPWpGaD
Valsartan—Loss of consciousness—Prednisone—Crohn's disease	0.00029	0.00164	CcSEcCtD
Valsartan—Myalgia—Prednisone—Crohn's disease	0.000281	0.00159	CcSEcCtD
Valsartan—Arthralgia—Prednisone—Crohn's disease	0.000281	0.00159	CcSEcCtD
Valsartan—Anxiety—Prednisone—Crohn's disease	0.00028	0.00158	CcSEcCtD
Valsartan—Unspecified disorder of skin and subcutaneous tissue—Prednisone—Crohn's disease	0.000279	0.00158	CcSEcCtD
Valsartan—ALB—Folate Metabolism—MPO—Crohn's disease	0.000279	0.0058	CbGpPWpGaD
Valsartan—AGTR1—G alpha (q) signalling events—RASGRP1—Crohn's disease	0.000278	0.0058	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism of lipids and lipoproteins—PLA2G4F—Crohn's disease	0.000274	0.00571	CbGpPWpGaD
Valsartan—AGTR1—GPCR ligand binding—GPR65—Crohn's disease	0.000272	0.00566	CbGpPWpGaD
Valsartan—SLCO1B3—SLC-mediated transmembrane transport—SLC11A1—Crohn's disease	0.000271	0.00565	CbGpPWpGaD
Valsartan—Oedema—Prednisone—Crohn's disease	0.000269	0.00152	CcSEcCtD
Valsartan—Anaphylactic shock—Prednisone—Crohn's disease	0.000269	0.00152	CcSEcCtD
Valsartan—Infection—Prednisone—Crohn's disease	0.000267	0.00151	CcSEcCtD
Valsartan—AGTR1—Allograft Rejection—IFNG—Crohn's disease	0.000265	0.00552	CbGpPWpGaD
Valsartan—Shock—Prednisone—Crohn's disease	0.000265	0.0015	CcSEcCtD
Valsartan—Nervous system disorder—Prednisone—Crohn's disease	0.000264	0.00149	CcSEcCtD
Valsartan—Skin disorder—Prednisone—Crohn's disease	0.000261	0.00148	CcSEcCtD
Valsartan—AGTR1—GPCRs, Class A Rhodopsin-like—PTGER4—Crohn's disease	0.000261	0.00544	CbGpPWpGaD
Valsartan—Anorexia—Prednisone—Crohn's disease	0.000257	0.00145	CcSEcCtD
Valsartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—CCR6—Crohn's disease	0.000254	0.00529	CbGpPWpGaD
Valsartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—RASGRP1—Crohn's disease	0.000249	0.00519	CbGpPWpGaD
Valsartan—AGTR1—Angiopoietin receptor Tie2-mediated signaling—TNF—Crohn's disease	0.000247	0.00515	CbGpPWpGaD
Valsartan—AGTR1—Allograft Rejection—CXCL8—Crohn's disease	0.000246	0.00513	CbGpPWpGaD
Valsartan—Musculoskeletal discomfort—Prednisone—Crohn's disease	0.000245	0.00139	CcSEcCtD
Valsartan—Insomnia—Prednisone—Crohn's disease	0.000243	0.00138	CcSEcCtD
Valsartan—Paraesthesia—Prednisone—Crohn's disease	0.000242	0.00137	CcSEcCtD
Valsartan—AGTR1—GPCR downstream signaling—MLN—Crohn's disease	0.000238	0.00496	CbGpPWpGaD
Valsartan—Dyspepsia—Prednisone—Crohn's disease	0.000237	0.00134	CcSEcCtD
Valsartan—AGTR1—Allograft Rejection—IL1B—Crohn's disease	0.000236	0.00492	CbGpPWpGaD
Valsartan—Decreased appetite—Prednisone—Crohn's disease	0.000234	0.00132	CcSEcCtD
Valsartan—SLCO1B3—Metabolism of lipids and lipoproteins—MTMR3—Crohn's disease	0.000233	0.00485	CbGpPWpGaD
Valsartan—Fatigue—Prednisone—Crohn's disease	0.000232	0.00131	CcSEcCtD
Valsartan—Constipation—Prednisone—Crohn's disease	0.00023	0.0013	CcSEcCtD
Valsartan—AGTR1—Signaling by GPCR—ACKR2—Crohn's disease	0.000228	0.00475	CbGpPWpGaD
Valsartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—PTGER4—Crohn's disease	0.000224	0.00466	CbGpPWpGaD
Valsartan—SLCO1B3—Transmembrane transport of small molecules—SLC22A5—Crohn's disease	0.000221	0.00461	CbGpPWpGaD
Valsartan—SLCO1B3—Transmembrane transport of small molecules—SLC22A4—Crohn's disease	0.000221	0.00461	CbGpPWpGaD
Valsartan—ALB—Selenium Micronutrient Network—MPO—Crohn's disease	0.000221	0.00461	CbGpPWpGaD
Valsartan—Gastrointestinal pain—Prednisone—Crohn's disease	0.00022	0.00125	CcSEcCtD
Valsartan—AGTR1—Signaling by GPCR—MLN—Crohn's disease	0.000216	0.00451	CbGpPWpGaD
Valsartan—Urticaria—Prednisone—Crohn's disease	0.000214	0.00121	CcSEcCtD
Valsartan—Abdominal pain—Prednisone—Crohn's disease	0.000213	0.0012	CcSEcCtD
Valsartan—SLCO1B1—SLC-mediated transmembrane transport—GCKR—Crohn's disease	0.000206	0.0043	CbGpPWpGaD
Valsartan—Hypersensitivity—Prednisone—Crohn's disease	0.000198	0.00112	CcSEcCtD
Valsartan—AGTR1—GPCR ligand binding—CCR6—Crohn's disease	0.000193	0.00403	CbGpPWpGaD
Valsartan—Asthenia—Prednisone—Crohn's disease	0.000193	0.00109	CcSEcCtD
Valsartan—Pruritus—Prednisone—Crohn's disease	0.00019	0.00108	CcSEcCtD
Valsartan—Diarrhoea—Prednisone—Crohn's disease	0.000184	0.00104	CcSEcCtD
Valsartan—SLCO1B1—Metabolism of lipids and lipoproteins—PLA2G4F—Crohn's disease	0.000184	0.00383	CbGpPWpGaD
Valsartan—SLCO1B1—SLC-mediated transmembrane transport—SLC11A1—Crohn's disease	0.000182	0.0038	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism of lipids and lipoproteins—FADS1—Crohn's disease	0.000181	0.00378	CbGpPWpGaD
Valsartan—ALB—Vitamin B12 Metabolism—CRP—Crohn's disease	0.00018	0.00375	CbGpPWpGaD
Valsartan—Dizziness—Prednisone—Crohn's disease	0.000178	0.00101	CcSEcCtD
Valsartan—AGTR1—Allograft Rejection—TNF—Crohn's disease	0.000171	0.00357	CbGpPWpGaD
Valsartan—Vomiting—Prednisone—Crohn's disease	0.000171	0.000968	CcSEcCtD
Valsartan—AGTR1—GPCR ligand binding—PTGER4—Crohn's disease	0.00017	0.00355	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism of lipids and lipoproteins—GPX4—Crohn's disease	0.00017	0.00354	CbGpPWpGaD
Valsartan—Rash—Prednisone—Crohn's disease	0.00017	0.00096	CcSEcCtD
Valsartan—Dermatitis—Prednisone—Crohn's disease	0.00017	0.000959	CcSEcCtD
Valsartan—Headache—Prednisone—Crohn's disease	0.000169	0.000954	CcSEcCtD
Valsartan—ALB—SLC-mediated transmembrane transport—SLC22A5—Crohn's disease	0.000167	0.00348	CbGpPWpGaD
Valsartan—ALB—SLC-mediated transmembrane transport—SLC22A4—Crohn's disease	0.000167	0.00348	CbGpPWpGaD
Valsartan—ALB—Vitamin B12 Metabolism—ICAM1—Crohn's disease	0.000165	0.00345	CbGpPWpGaD
Valsartan—AGTR1—GPCR downstream signaling—CCR9—Crohn's disease	0.000165	0.00344	CbGpPWpGaD
Valsartan—Nausea—Prednisone—Crohn's disease	0.00016	0.000904	CcSEcCtD
Valsartan—SLCO1B1—Metabolism of lipids and lipoproteins—MTMR3—Crohn's disease	0.000156	0.00326	CbGpPWpGaD
Valsartan—SLCO1B3—Transmembrane transport of small molecules—GCKR—Crohn's disease	0.000156	0.00325	CbGpPWpGaD
Valsartan—AGTR1—GPCR downstream signaling—GPR65—Crohn's disease	0.000153	0.0032	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—CCR9—Crohn's disease	0.00015	0.00312	CbGpPWpGaD
Valsartan—SLCO1B1—Transmembrane transport of small molecules—SLC22A4—Crohn's disease	0.000149	0.0031	CbGpPWpGaD
Valsartan—SLCO1B1—Transmembrane transport of small molecules—SLC22A5—Crohn's disease	0.000149	0.0031	CbGpPWpGaD
Valsartan—ALB—Folate Metabolism—CRP—Crohn's disease	0.000146	0.00305	CbGpPWpGaD
Valsartan—ALB—Platelet activation, signaling and aggregation—F5—Crohn's disease	0.000141	0.00293	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—GPR65—Crohn's disease	0.000139	0.0029	CbGpPWpGaD
Valsartan—SLCO1B3—Transmembrane transport of small molecules—SLC11A1—Crohn's disease	0.000138	0.00287	CbGpPWpGaD
Valsartan—CYP2C9—Metapathway biotransformation—GPX4—Crohn's disease	0.000137	0.00286	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—ACKR2—Crohn's disease	0.000135	0.00281	CbGpPWpGaD
Valsartan—ALB—Folate Metabolism—ICAM1—Crohn's disease	0.000135	0.00281	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—MLN—Crohn's disease	0.000128	0.00266	CbGpPWpGaD
Valsartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—TYK2—Crohn's disease	0.000127	0.00265	CbGpPWpGaD
Valsartan—ALB—Vitamin B12 Metabolism—IFNG—Crohn's disease	0.000126	0.00262	CbGpPWpGaD
Valsartan—AGTR1—Peptide ligand-binding receptors—CXCL8—Crohn's disease	0.000122	0.00254	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—PLA2G4F—Crohn's disease	0.000122	0.00254	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism of lipids and lipoproteins—FADS1—Crohn's disease	0.000122	0.00254	CbGpPWpGaD
Valsartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—JAK2—Crohn's disease	0.000121	0.00252	CbGpPWpGaD
Valsartan—ALB—SLC-mediated transmembrane transport—GCKR—Crohn's disease	0.000118	0.00246	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—TAGAP—Crohn's disease	0.000117	0.00243	CbGpPWpGaD
Valsartan—ALB—Selenium Micronutrient Network—CRP—Crohn's disease	0.000116	0.00243	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism of lipids and lipoproteins—GPX4—Crohn's disease	0.000114	0.00238	CbGpPWpGaD
Valsartan—ALB—Vitamin B12 Metabolism—IL1B—Crohn's disease	0.000112	0.00234	CbGpPWpGaD
Valsartan—AGTR1—GPCR downstream signaling—CCR6—Crohn's disease	0.000109	0.00228	CbGpPWpGaD
Valsartan—ALB—Selenium Micronutrient Network—ICAM1—Crohn's disease	0.000107	0.00223	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—PLA2G4F—Crohn's disease	0.000105	0.00219	CbGpPWpGaD
Valsartan—SLCO1B1—Transmembrane transport of small molecules—GCKR—Crohn's disease	0.000105	0.00218	CbGpPWpGaD
Valsartan—ALB—SLC-mediated transmembrane transport—SLC11A1—Crohn's disease	0.000104	0.00217	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—MTMR3—Crohn's disease	0.000104	0.00216	CbGpPWpGaD
Valsartan—ALB—Folate Metabolism—IFNG—Crohn's disease	0.000102	0.00214	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—RSPO3—Crohn's disease	0.000102	0.00213	CbGpPWpGaD
Valsartan—CYP2C9—Arachidonic acid metabolism—PTGS2—Crohn's disease	0.0001	0.00209	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—CCR6—Crohn's disease	9.93e-05	0.00207	CbGpPWpGaD
Valsartan—SLCO1B3—SLC-mediated transmembrane transport—ALB—Crohn's disease	9.77e-05	0.00204	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—SEL1L—Crohn's disease	9.68e-05	0.00202	CbGpPWpGaD
Valsartan—AGTR1—GPCR downstream signaling—PTGER4—Crohn's disease	9.63e-05	0.00201	CbGpPWpGaD
Valsartan—SLCO1B1—Transmembrane transport of small molecules—SLC11A1—Crohn's disease	9.26e-05	0.00193	CbGpPWpGaD
Valsartan—ALB—Folate Metabolism—IL1B—Crohn's disease	9.14e-05	0.0019	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—MTMR3—Crohn's disease	8.94e-05	0.00186	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—CCR9—Crohn's disease	8.85e-05	0.00185	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—PTGER4—Crohn's disease	8.74e-05	0.00182	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—PLA2G4F—Crohn's disease	8.6e-05	0.00179	CbGpPWpGaD
Valsartan—ALB—Transmembrane transport of small molecules—SLC22A4—Crohn's disease	8.5e-05	0.00177	CbGpPWpGaD
Valsartan—ALB—Transmembrane transport of small molecules—SLC22A5—Crohn's disease	8.5e-05	0.00177	CbGpPWpGaD
Valsartan—ALB—Platelet activation, signaling and aggregation—IL3—Crohn's disease	8.43e-05	0.00176	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—GPR65—Crohn's disease	8.23e-05	0.00172	CbGpPWpGaD
Valsartan—AGTR1—GPCR downstream signaling—IL3—Crohn's disease	8.2e-05	0.00171	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—PLA2G4F—Crohn's disease	8.19e-05	0.00171	CbGpPWpGaD
Valsartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—CXCL8—Crohn's disease	8.19e-05	0.00171	CbGpPWpGaD
Valsartan—ALB—Platelet activation, signaling and aggregation—RASGRP1—Crohn's disease	8.15e-05	0.0017	CbGpPWpGaD
Valsartan—ALB—Vitamin B12 Metabolism—TNF—Crohn's disease	8.15e-05	0.0017	CbGpPWpGaD
Valsartan—ALB—Selenium Micronutrient Network—IFNG—Crohn's disease	8.14e-05	0.0017	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—FADS1—Crohn's disease	8.08e-05	0.00168	CbGpPWpGaD
Valsartan—AGTR1—GPCR downstream signaling—RASGRP1—Crohn's disease	7.93e-05	0.00165	CbGpPWpGaD
Valsartan—ALB—Selenium Micronutrient Network—PTGS2—Crohn's disease	7.8e-05	0.00163	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—GPX4—Crohn's disease	7.56e-05	0.00158	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—IL3—Crohn's disease	7.45e-05	0.00155	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—MTMR3—Crohn's disease	7.31e-05	0.00152	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—GCKR—Crohn's disease	7.3e-05	0.00152	CbGpPWpGaD
Valsartan—ALB—Selenium Micronutrient Network—IL1B—Crohn's disease	7.26e-05	0.00151	CbGpPWpGaD
Valsartan—ALB—Hemostasis—F5—Crohn's disease	7.25e-05	0.00151	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—RASGRP1—Crohn's disease	7.2e-05	0.0015	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—MTMR3—Crohn's disease	6.96e-05	0.00145	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—FADS1—Crohn's disease	6.96e-05	0.00145	CbGpPWpGaD
Valsartan—ALB—Folate Metabolism—TNF—Crohn's disease	6.63e-05	0.00138	CbGpPWpGaD
Valsartan—ALB—Vitamin B12 Metabolism—IL6—Crohn's disease	6.58e-05	0.00137	CbGpPWpGaD
Valsartan—SLCO1B1—SLC-mediated transmembrane transport—ALB—Crohn's disease	6.56e-05	0.00137	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—GPX4—Crohn's disease	6.52e-05	0.00136	CbGpPWpGaD
Valsartan—AGTR1—GPCR ligand binding—CXCL8—Crohn's disease	6.23e-05	0.0013	CbGpPWpGaD
Valsartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—Crohn's disease	6.21e-05	0.00129	CbGpPWpGaD
Valsartan—ALB—Transmembrane transport of small molecules—GCKR—Crohn's disease	5.99e-05	0.00125	CbGpPWpGaD
Valsartan—ALB—Platelet activation, signaling and aggregation—IL2RA—Crohn's disease	5.91e-05	0.00123	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—CCR6—Crohn's disease	5.87e-05	0.00122	CbGpPWpGaD
Valsartan—AGTR1—GPCR downstream signaling—IL2RA—Crohn's disease	5.74e-05	0.0012	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—FADS1—Crohn's disease	5.7e-05	0.00119	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—FADS1—Crohn's disease	5.43e-05	0.00113	CbGpPWpGaD
Valsartan—ALB—Folate Metabolism—IL6—Crohn's disease	5.35e-05	0.00112	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—GPX4—Crohn's disease	5.34e-05	0.00111	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—RBX1—Crohn's disease	5.3e-05	0.00111	CbGpPWpGaD
Valsartan—ALB—Transmembrane transport of small molecules—SLC11A1—Crohn's disease	5.29e-05	0.0011	CbGpPWpGaD
Valsartan—ALB—Selenium Micronutrient Network—TNF—Crohn's disease	5.27e-05	0.0011	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism of lipids and lipoproteins—ALB—Crohn's disease	5.22e-05	0.00109	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—IL2RA—Crohn's disease	5.22e-05	0.00109	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—PTGER4—Crohn's disease	5.16e-05	0.00108	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—GPX4—Crohn's disease	5.08e-05	0.00106	CbGpPWpGaD
Valsartan—SLCO1B3—Transmembrane transport of small molecules—ALB—Crohn's disease	4.96e-05	0.00103	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—GCKR—Crohn's disease	4.91e-05	0.00102	CbGpPWpGaD
Valsartan—ALB—Metabolism—PLA2G4F—Crohn's disease	4.68e-05	0.000975	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—UBE2D1—Crohn's disease	4.65e-05	0.000969	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism of lipids and lipoproteins—PTGS2—Crohn's disease	4.57e-05	0.000952	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—RIPK2—Crohn's disease	4.51e-05	0.00094	CbGpPWpGaD
Valsartan—ALB—Hemostasis—ITGA4—Crohn's disease	4.46e-05	0.000929	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—IL3—Crohn's disease	4.4e-05	0.000917	CbGpPWpGaD
Valsartan—ALB—Hemostasis—IL3—Crohn's disease	4.35e-05	0.000906	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—RASGRP1—Crohn's disease	4.25e-05	0.000887	CbGpPWpGaD
Valsartan—ALB—Selenium Micronutrient Network—IL6—Crohn's disease	4.25e-05	0.000886	CbGpPWpGaD
Valsartan—ALB—Hemostasis—RASGRP1—Crohn's disease	4.2e-05	0.000876	CbGpPWpGaD
Valsartan—ALB—Metabolism—MTMR3—Crohn's disease	3.98e-05	0.000829	CbGpPWpGaD
Valsartan—ALB—Platelet activation, signaling and aggregation—JAK2—Crohn's disease	3.97e-05	0.000827	CbGpPWpGaD
Valsartan—AGTR1—GPCR downstream signaling—JAK2—Crohn's disease	3.86e-05	0.000805	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—SOCS1—Crohn's disease	3.85e-05	0.000803	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—PLA2G4F—Crohn's disease	3.83e-05	0.000798	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—TYK2—Crohn's disease	3.67e-05	0.000766	CbGpPWpGaD
Valsartan—AGTR1—GPCR downstream signaling—CXCL8—Crohn's disease	3.52e-05	0.000734	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism of lipids and lipoproteins—ALB—Crohn's disease	3.51e-05	0.000731	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—JAK2—Crohn's disease	3.51e-05	0.000731	CbGpPWpGaD
Valsartan—SLCO1B1—Transmembrane transport of small molecules—ALB—Crohn's disease	3.33e-05	0.000695	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—SMAD3—Crohn's disease	3.33e-05	0.000693	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—MTMR3—Crohn's disease	3.26e-05	0.000679	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—CXCL8—Crohn's disease	3.2e-05	0.000667	CbGpPWpGaD
Valsartan—ALB—Metabolism—FADS1—Crohn's disease	3.1e-05	0.000646	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—IL2RA—Crohn's disease	3.08e-05	0.000642	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism of lipids and lipoproteins—PTGS2—Crohn's disease	3.07e-05	0.000639	CbGpPWpGaD
Valsartan—ALB—Hemostasis—IL2RA—Crohn's disease	3.04e-05	0.000634	CbGpPWpGaD
Valsartan—ALB—Metabolism—GPX4—Crohn's disease	2.9e-05	0.000605	CbGpPWpGaD
Valsartan—ALB—Metabolism—GCKR—Crohn's disease	2.8e-05	0.000584	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—FADS1—Crohn's disease	2.54e-05	0.000529	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—GPX4—Crohn's disease	2.38e-05	0.000495	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—ALB—Crohn's disease	2.32e-05	0.000484	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—GCKR—Crohn's disease	2.29e-05	0.000478	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—TYK2—Crohn's disease	2.17e-05	0.000452	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—JAK2—Crohn's disease	2.07e-05	0.000432	CbGpPWpGaD
Valsartan—ALB—Hemostasis—JAK2—Crohn's disease	2.05e-05	0.000426	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—PTGS2—Crohn's disease	2.03e-05	0.000424	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—CXCL8—Crohn's disease	1.89e-05	0.000394	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—IL6—Crohn's disease	1.8e-05	0.000375	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—PTGS2—Crohn's disease	1.75e-05	0.000365	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—ALB—Crohn's disease	1.64e-05	0.000342	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—ALB—Crohn's disease	1.56e-05	0.000325	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—STAT3—Crohn's disease	1.52e-05	0.000317	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—Crohn's disease	1.43e-05	0.000299	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—PTGS2—Crohn's disease	1.37e-05	0.000285	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—IL6—Crohn's disease	1.06e-05	0.000221	CbGpPWpGaD
Valsartan—ALB—Metabolism—PTGS2—Crohn's disease	7.81e-06	0.000163	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—ALB—Crohn's disease	7.3e-06	0.000152	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—PTGS2—Crohn's disease	6.39e-06	0.000133	CbGpPWpGaD
